FLASH - Biocorp - Strong Buy - TP: €36.80
The sharp rise in operating expenses (€12.58m, +21%), linked to the forthcoming Mallya launches, keeps the company in the R&D phase with a Net income of €0.7m, despite a sales increase to €11.7m (+14%), which is still mainly composed of milestones.Biocorp Production SA is a France-based company, which is specialised in the development and manufacturing of medical and drug delivery devices.
Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.